Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-09-06
Based on 599 first isolates · URO · Cystitis (lower UTI) · 2025-09-07 → 2026-09-06
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 86 % (83 %–88 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
86 %
88 %
n = 65
meropenem MEM
trend · Escherichia coli reserve
83 %
83 %
n = 65
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
77 %
n = 65
ciprofloxacin CIP
trend · Escherichia coli
76 %
72 %
n = 65
ceftriaxone CRO
trend · Escherichia coli
75 %
72 %
n = 65
mecillinam MEC
trend · Escherichia coli lower UTI only
74 %
71 %
n = 65
71 %
66 %
n = 65
trimethoprim TMP
trend · Escherichia coli lower UTI only
66 %
58 %
n = 65
52 %
46 %
n = 65
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
15 %
n = 65
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
5 %
5 %
n = 65
4 %
5 %
n = 65

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
6 %
Staphylococcus aureus
5 %
Pseudomonas aeruginosa
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.